Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 7/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.62 |
| ▸ | STK3 | Q13188 | 4/20 | 0.62 |
| ▸ | CDC7 | O00311 | 1/20 | 0.62 |
| ▸ | ROS1 | P08922 | 1/20 | 0.62 |
| ▸ | KIT | P10721 | 1/20 | 0.62 |
| ▸ | MARK3 | P27448 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.62 |
| ▸ | CDK8 | P49336 | 1/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.62 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.62 |
| ▸ | MELK | Q14680 | 1/20 | 0.62 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.62 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.62 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.62 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.62 |
| ▸ | STK4 | Q13043 | 3/20 | 0.61 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.49 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2253909 | 0.86 | AKT1 (0.68) | AKT1LRRK2STK3STK4MAP3K6 | |
| SCHEMBL20640921 | 0.84 | AKT1 (0.85) | AKT1LRRK2STK3CDC7KIT | |
| SCHEMBL3955185 | 0.83 | LRRK2 (0.63) | AKT1LRRK2STK3CDC7ROS1 | |
| SCHEMBL4298450 | 0.81 | AKT1 (0.64) | AKT1LRRK2STK3CDC7ROS1 | |
| SCHEMBL4005724 | 0.79 | LRRK2 (0.61) | AKT1LRRK2STK3CDC7ROS1 | |
| SCHEMBL3955638 | 0.79 | LRRK2 (0.79) | LRRK2STK3CDC7ROS1KIT | |
| SCHEMBL4870346 | 0.78 | AKT1 (0.64) | AKT1LRRK2STK3CDC7MARK3 | |
| SCHEMBL3536255 | 0.78 | LRRK2 (0.58) | AKT1LRRK2STK3CDC7ROS1 | |
| SCHEMBL3954467 | 0.78 | LRRK2 (0.58) | AKT1LRRK2STK3CDC7ROS1 | |
| SCHEMBL3535567 | 0.78 | CHUK (0.67) | LRRK2STK3CDC7ROS1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | claimed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | claimed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | claimed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | claimed |
| EP-1087971-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065909-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | claimed |
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1087971-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065909-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | AKT1 595/4885LRRK2 972/4885STK3 211/4885 |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | AKT1 595/4885LRRK2 972/4885STK3 211/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | AKT1 789/4885LRRK2 1190/4885STK3 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.